Hormetic effects of EGC and EGCG on CES1 activity and its rescue from oxidative stress in rat liver S9
- PMID: 37353134
- DOI: 10.1016/j.cbi.2023.110612
Hormetic effects of EGC and EGCG on CES1 activity and its rescue from oxidative stress in rat liver S9
Abstract
Carboxylesterase 1 (CES1) is a hydrolytic enzyme that plays an important role in the activation or deactivation of many therapeutic agents, thus affecting their pharmacokinetic and pharmacodynamic outcomes. Using rat liver S9 as an enzyme source and enalapril as a CES1 substrate, the present study examined effects of a number of flavonoids on the formation of enalaprilat (the active form of enalapril) produced by CES1-mediated hydrolysis. While a majority of flavonoids tested showed inhibition on CES1, an unexpected hormetic effect was observed for epigallocatechin (EGC) and epigallocatechin gallate (EGCG), i.e., stimulatory effect at low concentrations and enzyme inhibition at high concentrations. Further experiments revealed that oxidative stress caused by hydrogen peroxide, arachidonic acid plus iron, and oxidized low density lipoproteins (oxLOL) reduced CES1 activity in rat liver S9 and the loss of CES1 enzyme activity could be rescued largely by EGC or EGCG. In contrast, such effects were minimal in human liver S9, probably due to the presence of a higher ratio of reduced vs oxidized forms of glutathione. The above findings suggest that the polyphenolic nature of EGC or EGCG might be responsible for rescuing CES1 activity under oxidative stress. Because of the importance of CES1 in drug activation or deactivation and rat liver S9 as a versatile in vitro system used for drug metabolism studies and drug safety assessment, caution should be exercised to avoid potential biases for data interpretation and decision making when CES1 activity in rat liver S9 is evaluated with dependency on experimental conditions.
Keywords: CES1; EGC and EGCG; Flavanols; Hormetic effects; Stimulation.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Pharmacogenetic study of CES1 gene and enalapril efficacy.J Appl Genet. 2024 Jan 23. doi: 10.1007/s13353-024-00831-w. Online ahead of print. J Appl Genet. 2024. PMID: 38261266 Review.
-
Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase.Drug Metab Pharmacokinet. 2021 Aug;39:100397. doi: 10.1016/j.dmpk.2021.100397. Epub 2021 Apr 20. Drug Metab Pharmacokinet. 2021. PMID: 34171773
-
Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.Drug Metab Dispos. 2020 Mar;48(3):230-244. doi: 10.1124/dmd.119.089680. Epub 2019 Dec 23. Drug Metab Dispos. 2020. PMID: 31871135 Free PMC article. Review.
-
Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril.Br J Clin Pharmacol. 2015 Nov;80(5):1131-8. doi: 10.1111/bcp.12667. Epub 2015 Jun 11. Br J Clin Pharmacol. 2015. PMID: 25919042 Free PMC article. Clinical Trial.
-
In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors.Drug Metab Dispos. 2014 Jan;42(1):126-33. doi: 10.1124/dmd.113.053512. Epub 2013 Oct 18. Drug Metab Dispos. 2014. PMID: 24141856
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous